TY - JOUR
T1 - Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease
AU - NASH CRN
AU - Wang, Andrew
AU - Blackford, Amanda L.
AU - Behling, Cynthia
AU - Wilson, Laura
AU - Newton, Kimberly P.
AU - Xanthakos, Stavra A.
AU - Fishbein, Mark H.
AU - Vos, Miriam B.
AU - Mouzaki, Marialena
AU - Molleston, Jean P.
AU - Jain, Ajay K.
AU - Hertel, Paula
AU - Harlow Adams, Kathryn
AU - Schwimmer, Jeffrey B.
AU - Cavallo, Laurel
AU - Garner, Donna
AU - Hertel, Paula M.
AU - Mysore, Krupa R.
AU - Ortega, Taira Illescas
AU - Tessier, Mary Elizabeth
AU - Triggs, Nicole
AU - Tsai, Cynthia
AU - Arce-Clachar, Ana Catalina
AU - Bramlage, Kristin
AU - Cecil, Kim
AU - Mouzaki, Marialena
AU - Popelar, Ann
AU - Trout, Andrew
AU - Xanthakos, Stavra
AU - Alazraki, Adina
AU - Garcia, Carmen
AU - Jara-Garra, Jorge
AU - Karpen, Saul
AU - Vos, Miriam
AU - Cummings, Oscar W.
AU - Adams, Kathryn Harlow
AU - Jarasvaraparn, Chaowapong
AU - Klipsch, Ann
AU - Molleston, Jean P.
AU - Morlan, Wendy
AU - Ragozzinom, Emily
AU - Chapin, Catherine
AU - Fishbein, Mark H.
AU - Carpenter, Danielle
AU - Cattoor, Theresa
AU - Clark, Jeanne M.
AU - Desanto, Jennifer M.
AU - Tonascia, James
AU - Woreta, Tinsay
AU - Yates, Katherine P.
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/6
Y1 - 2024/6
N2 - Background and Aims: Liver fibrosis is common in children with NAFLD and is an important determinant of outcomes. High-performing noninvasive models to assess fibrosis in children are needed. The objectives of this study were to evaluate the performance of existing pediatric and adult fibrosis prediction models and to develop a clinical prediction rule for identifying moderate-to-severe fibrosis in children with NAFLD. Approach and Results: We enrolled children with biopsy-proven NAFLD in the Nonalcoholic Steatohepatitis Clinical Research Network within 90 days of liver biopsy. We staged liver fibrosis in consensus using the Nonalcoholic Steatohepatitis Clinical Research Network scoring system. We evaluated existing pediatric and adult models for fibrosis and developed a new pediatric model using the least absolute shrinkage and selection operator with linear and spline terms for discriminating moderate-to-severe fibrosis from none or mild fibrosis. The model was internally validated with 10-fold cross-validation. We evaluated 1055 children with NAFLD, of whom 26% had moderate-to-severe fibrosis. Existing models performed poorly in classifying fibrosis in children, with area under the receiver operator curves (AUC) ranging from 0.57 to 0.64. In contrast, our new model, fibrosis in pediatric NAFLD was derived from fourteen common clinical variables and had an AUC of 0.79 (95% CI: 0.77-0.81) with 72% sensitivity and 76% specificity for identifying moderate-to-severe fibrosis. Conclusion: Existing fibrosis prediction models have limited clinical utility in children with NAFLD. Fibrosis in pediatric NAFLD offers improved performance characteristics for risk stratification by identifying moderate-to-severe fibrosis in children with NAFLD.
AB - Background and Aims: Liver fibrosis is common in children with NAFLD and is an important determinant of outcomes. High-performing noninvasive models to assess fibrosis in children are needed. The objectives of this study were to evaluate the performance of existing pediatric and adult fibrosis prediction models and to develop a clinical prediction rule for identifying moderate-to-severe fibrosis in children with NAFLD. Approach and Results: We enrolled children with biopsy-proven NAFLD in the Nonalcoholic Steatohepatitis Clinical Research Network within 90 days of liver biopsy. We staged liver fibrosis in consensus using the Nonalcoholic Steatohepatitis Clinical Research Network scoring system. We evaluated existing pediatric and adult models for fibrosis and developed a new pediatric model using the least absolute shrinkage and selection operator with linear and spline terms for discriminating moderate-to-severe fibrosis from none or mild fibrosis. The model was internally validated with 10-fold cross-validation. We evaluated 1055 children with NAFLD, of whom 26% had moderate-to-severe fibrosis. Existing models performed poorly in classifying fibrosis in children, with area under the receiver operator curves (AUC) ranging from 0.57 to 0.64. In contrast, our new model, fibrosis in pediatric NAFLD was derived from fourteen common clinical variables and had an AUC of 0.79 (95% CI: 0.77-0.81) with 72% sensitivity and 76% specificity for identifying moderate-to-severe fibrosis. Conclusion: Existing fibrosis prediction models have limited clinical utility in children with NAFLD. Fibrosis in pediatric NAFLD offers improved performance characteristics for risk stratification by identifying moderate-to-severe fibrosis in children with NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85193561041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193561041&partnerID=8YFLogxK
U2 - 10.1097/HEP.0000000000000644
DO - 10.1097/HEP.0000000000000644
M3 - Article
C2 - 37870272
AN - SCOPUS:85193561041
SN - 0270-9139
VL - 79
SP - 1381
EP - 1392
JO - Hepatology
JF - Hepatology
IS - 6
ER -